| identifier: | 1866660 |
| description: |
epitope description:S17, I21, Q25, H27, V29, E31, Y32, D33, P34, T35, I36, E37, D38, S39, Y40, Q61, E63, Y64
antigen name:GTPase HRas
host organism:Homo sapiens
antibody name:anti-RAS
|
| aggregation: |
instance of dataset
|
| availability: |
available
|
| primaryPublications: |
17568777 |
| authorizations: |
registration not required
|
| accessURL: |
http://www.iedb.org/reference/1018825 |
| landingPage: |
http://www.iedb.org/assay/1866660 |
| type: |
Literature
|
| publicationVenue: |
EMBO J
|
| dates: |
2007
|
| study type: | b cell assays |
| subject species: | Homo sapiens |
| fullName: |
Tomoyuki Tanaka
Roger L Williams
Terence H Rabbitts
|
| method: |
surface plasmon resonance (SPR)
|
| name: |
Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS.
|
| description: |
Epitope residues are calculated from the structure [PDB: 2UZI] as the antigen residues at 4 Å
distance from the antibody.
The epitope-specific anti-RAS scFv#6 intrabody bound to activated HRAS-GTP(gammaS) with high affinity. The single VH#6 domain (iDab#6) without the VL domain had an affinity of KD = 6.2 nM (k on = 2.93 x 105 and k off = 1.82 x 10-3). Anti-RAS does not bind to HRAS-GDP. The single VH#6 domain (iDab#6) bound to oncogenic HRAS with mutations at either residue 12 or 61 with higher affinity than to wt HRAS. The intrabody iDab#6 did not bind to RAS with mutations at residues 10, 15, 17 or 57, and mutations at residues 33, 35, 38, 40, or 64 reduced binding.
|
| name: |
iedb
|
| homePage: |
http://www.iedb.org |